摘要
目的评价丁苯酞治疗分支动脉粥样硬化病脑梗死的临床疗效及安全性。方法采用随机对照设计,将64例急性脑梗死患者,随机分为丁苯酞治疗组(32例)和对照组(32例)。两组患者诊断均采用高木诚等提出的诊断标准进行诊断,全部患者均给予口服阿司匹林、阿托伐他汀钙,静脉滴注奥扎格雷钠。治疗组在常规治疗的基础上使用丁苯酞50 mg·d-1,静脉滴注,连续治疗14d。两组患者均在治疗前后进行神经功能缺损程度评分(NIHSS)和日常生活活动能力评分(BI)。结果两组患者治疗前NIHSS评分差异无统计学意义(P>0.05),治疗后NIHSS评分均较治疗前降低(P<0.05);治疗组治疗后NIHSS评分明显低于对照组(P<0.05)。两组患者治疗前BI评分差异无统计学意义(P>0.05),治疗后BI评分均较治疗前增高(P<0.05);治疗组治疗后BI评分明显高于对照组(P<0.05)。治疗过程中未见不良反应。结论丁苯酞能显著改善分支动脉粥样硬化病脑梗死患者的神经功能缺损及日常生活活动能力,疗效确切,安全性好。
Objective To test efficacy and safety of butylphthalide and sodium chloride injection in the treatment of branch atheromatous disease.Methods A total of 64 patients with acute cerebral infarction were randomly divided into treatment group (n=32) and control group(n=32).The two groups met the criteria for BAD proposed by Chen L.All patients were given aspirin,atorvastatin calcium and ozagrel.The treatment group were treated with butylphthalide and sodium chloride injection 50 mg· d-1 ivdrip bid 14d.The neurological deficit scores and activities of daily living scores were examined before and after treatment.Results The NIHSS scores of the two groups before treatment were not statistically significant(P>0.05),and NIHSS scores after treatment were lower than those before treatment(P<0.05).NIHSS scores of the treatment group were significantly lower than the control group after treatment(P<0.05).The BI scores of the two groups before treatment were not statistically significant (P>0.05),and BI scores after treatment were higher than those before treatment(P<0.05).BI scores of the treatment group were significantly higher than the control group after treatment(P<0.05).No adverse reaction was observed.Conclusion Butyphthalide can significantly improve the neurological deficits and activities of daily living of the patients with branch atheromatous disease.
出处
《脑与神经疾病杂志》
2014年第5期340-343,共4页
Journal of Brain and Nervous Diseases
关键词
脑梗死
分支动脉粥样硬化病
丁苯酞
豆纹动脉
脑桥旁正中动脉
Cerebral infarction
Branch atheromatous disease
Butylphthalide
Lenticulostriate artery
Paramedian pontine artery